The Trump administration has finalized a deal with drugmaker AbbVie to cut the cost of certain medicines, marking the latest pact as part of its “Most Favored Nation” pricing initiative.

As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on ...

North Chicago-based AbbVie has become the latest drugmaker to reach a deal with the Trump administration on drug prices in ...

AbbVie commits to lowering Medicaid drug prices and investing $100 billion in US R&D and capital investments over the next decade. The TrumpRx program will expand direct-to-patient offerings, ...

AbbVie has also pledged to participate in TrumpRx and offer many of its products, including Humira, on a direct-to-patient ...

Look into AbbVie's strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent ...